It’s going to be a big summer for the microbiome
Three companies — Finch Therapeutics, Seres Therapeutics, and Rebiotix — are on track to report pivotal data on microbiome therapies meant to treat a serious infection in the coming months. And those plans remain intact, outbreak or no.
As STAT’s Kate Sheridan reports, leaders from the bruised but hopeful field gathered virtually for the Chardan Microbiome Medicines Summit, initially slated for New York but moved online in the name of social distancing.
The overarching theme was that, despite some clinical disappointments and safety concerns, the microbiome space has turned something of a corner when it comes to understanding how helpful bacteria can quell infection. Manufacturing remains a challenge, and the pandemic could yet scramble schedules, but drug developers are keeping the faith. Now we wait for data.
Read more.
As STAT’s Kate Sheridan reports, leaders from the bruised but hopeful field gathered virtually for the Chardan Microbiome Medicines Summit, initially slated for New York but moved online in the name of social distancing.
The overarching theme was that, despite some clinical disappointments and safety concerns, the microbiome space has turned something of a corner when it comes to understanding how helpful bacteria can quell infection. Manufacturing remains a challenge, and the pandemic could yet scramble schedules, but drug developers are keeping the faith. Now we wait for data.
Read more.
.png)
No hay comentarios:
Publicar un comentario